Stem cells and beta cell replacement therapy: a prospective health technology assessment study

Wallner, Klemens; Pedroza, Rene G.; Awotwe, Isaac; Piret, James M.; Senior, Peter A.; Shapiro, A. M. James; McCabe, Christopher

doi:10.1186/s12902-018-0233-7

BMC Endocrine Disorders

Table 2 Results for different scenarios using adherent cell culture (means per patient)

From: Stem cells and beta cell replacement therapy: a prospective health technology assessment study

Scenario						Cost		Benefit		ICER	EVPI		Maximum Partial EVPI Dose Costs
Index	Production mode	Supply per facility	COGd factor	Regulatory factor	Variation (RSD^a)	Strategy	Difference	Strategy	Difference		WTP per QALY
Index	Production mode	Supply per facility	COGd factor	Regulatory factor	Variation (RSD^a)	Strategy	Difference	Strategy	Difference		$50,000	$100,000
Scenarios with 3% discount rate
Comp1	(Comparator 3%)					74,230		11.12
Adh1	Local	50	4	1.2	22.5%	629,181	554,951	13.85	2.73	203,203	18	4220	90,957
Adh2	Local	50	4	1.2	50.0%	628,936	554,707	13.85	2.73	203,114	677	19,749	135,128
Adh3	Local	50	4	1.8	22.5%	876,810	802,580	13.85	2.73	293,877	2	721	143,704
Adh4	Local	50	4	1.8	50.0%	873,510	799,281	13.85	2.73	292,669	169	8061	214,930
Adh5	Scale out local	50	3	1.2	22.5%	504,903	430,673	13.85	2.73	157,697	87	11,725	69,691
Adh6	Scale out local	50	3	1.2	50.0%	504,835	430,606	13.85	2.73	157,673	1493	32,911	106,144
Adh7	Scale out local	50	3	1.8	22.5%	690,050	615,819	13.85	2.73	225,492	11	2623	102,737
Adh8	Scale out local	50	3	1.8	50.0%	688,524	614,294	13.85	2.73	224,933	432	15,297	167,801
Adh9	Scale out local	50	8	1.8	22.5%	1,616,386	1,542,156	13.85	2.73	564,685	0	19	273,576
Adh10	Scale out local	50	8	1.8	50.0%	1,606,953	1,532,722	13.85	2.73	561,231	9	1052	443,892
Adh11	Large scale	500	4	1.2	22.5%	536,915	462,685	13.85	2.73	169,420	127	11,621	78,153
Adh12	Large scale	500	4	1.2	50.0%	536,730	462,501	13.85	2.73	169,351	1501	31,043	124,247
Adh13	Large scale	500	4	1.8	22.5%	738,478	664,248	13.85	2.73	243,225	24	3085	117,352
Adh14	Large scale	500	4	1.8	50.0%	736,541	662,311	13.85	2.73	242,516	499	14,700	192,416
Adh15	Scale out large	500	3	1.2	22.5%	435,777	361,548	13.85	2.73	132,386	453	24,792	63,732
Adh16	Scale out large	500	3	1.2	50.0%	435,661	361,432	13.85	2.73	132,344	3005	47,591	96,481
Adh17	Scale out large	500	3	1.8	22.5%	586,704	512,474	13.85	2.73	187,650	82	8143	93,084
Adh18	Scale out large	500	3	1.8	50.0%	585,166	510,936	13.85	2.73	187,088	1118	25,291	148,572
Scenarios with 0% discount rate
Comp2	(Comparator 0%)					113,175		16.09
Adh19	Local	50	4	1.2	22.5%	663,514	550,339	20.60	4.51	122,159	1395	52,620	90,906
Adh20	Scale out large	500	3	1.2	22.5%	470,111	356,936	20.60	4.51	79,230	11,315	30,540	63,752
Scenarios with 5% discount rate
Comp3	(Comparator 5%)					58,559		9.09
Adh21	Local	50	4	1.2	22.5%	616,693	558,134	11.18	2.09	267,339	0	614	90,973
Adh22	Scale out large	500	3	1.2	22.5%	423,290	364,731	11.18	2.09	174,701	32	6396	63,730

All scenarios used the base case assumptions with the described structural deviations. Cost measure is Canadian dollar (2016). Benefit measure is QALY. All result numbers are rounded and including sampling variation
^aRelative standard deviation (RSD; i.e. SD as percentage of the mean) that was assumed for the two factors

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com